446 related articles for article (PubMed ID: 28441920)
21. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.
Pardanani A; Gotlib J; Roberts AW; Wadleigh M; Sirhan S; Kawashima J; Maltzman JA; Shao L; Gupta V; Tefferi A
Leukemia; 2018 Apr; 32(4):1035-1038. PubMed ID: 29263442
[No Abstract] [Full Text] [Related]
22. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
23. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
24. Ruxolitinib for the treatment of myelofibrosis.
Ostojic A; Vrhovac R; Verstovsek S
Drugs Today (Barc); 2011 Nov; 47(11):817-27. PubMed ID: 22146225
[TBL] [Abstract][Full Text] [Related]
25. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
26. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
Tremblay D; Hoffman R
Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
[TBL] [Abstract][Full Text] [Related]
27. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract][Full Text] [Related]
28. Cytopenic myelofibrosis: prevalence, relevance, and treatment.
Vachhani P; Verstovsek S; Bose P
Expert Opin Pharmacother; 2023 Jun; 24(8):901-912. PubMed ID: 37070147
[TBL] [Abstract][Full Text] [Related]
29. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
De SK
Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
[TBL] [Abstract][Full Text] [Related]
30. JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside.
Gotlib J
Hematology Am Soc Hematol Educ Program; 2013; 2013():529-37. PubMed ID: 24319228
[TBL] [Abstract][Full Text] [Related]
31. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of ruxolitinib for myelofibrosis.
Santos FP; Verstovsek S
Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Ostojic A; Vrhovac R; Verstovsek S
Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
[TBL] [Abstract][Full Text] [Related]
35. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
Porpaczy E; Tripolt S; Hoelbl-Kovacic A; Gisslinger B; Bago-Horvath Z; Casanova-Hevia E; Clappier E; Decker T; Fajmann S; Fux DA; Greiner G; Gueltekin S; Heller G; Herkner H; Hoermann G; Kiladjian JJ; Kolbe T; Kornauth C; Krauth MT; Kralovics R; Muellauer L; Mueller M; Prchal-Murphy M; Putz EM; Raffoux E; Schiefer AI; Schmetterer K; Schneckenleithner C; Simonitsch-Klupp I; Skrabs C; Sperr WR; Staber PB; Strobl B; Valent P; Jaeger U; Gisslinger H; Sexl V
Blood; 2018 Aug; 132(7):694-706. PubMed ID: 29907599
[TBL] [Abstract][Full Text] [Related]
36. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
Diaz AE; Mesa RA
Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
[TBL] [Abstract][Full Text] [Related]
37. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Lancman G; Mascarenhas J
Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
[TBL] [Abstract][Full Text] [Related]
38. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
39. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Mascarenhas JO; Talpaz M; Gupta V; Foltz LM; Savona MR; Paquette R; Turner AR; Coughlin P; Winton E; Burn TC; O'Neill P; Clark J; Hunter D; Assad A; Hoffman R; Verstovsek S
Haematologica; 2017 Feb; 102(2):327-335. PubMed ID: 27789678
[TBL] [Abstract][Full Text] [Related]
40. Janus activated kinase inhibition in myelofibrosis.
Malhotra H
Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]